News

The University of Kentucky is a site for KidCOVE, a national trial by Moderna to test the safety and effectiveness of its COVID-19 vaccine in children. The vaccine may protect young children 6 months to those under 12 years of age if they come into contact with the SARS-CoV-2 virus. 

Researchers found that most Americans were willing to take a COVID-19 test and valued having options when it came to how, when and where they were tested.

In January 2021, the Center for Muscle Biology (CMB) officially transferred from the UK College of Medicine to become a part of the UK College of Health Sciences.

Immunocompromised individuals who have previously received two doses of either the Pfizer or the Moderna COVID-19 vaccines are eligible to request a third dose.

The University of Kentucky has been selected as a site for a trial to assess dose levels of a Johnson & Johnson booster shot.

University of Kentucky alumnus Mosoka Fallah, Ph.D., is on the frontlines of the COVID-19 pandemic in Liberia.

The University of Kentucky Center of Excellence in Rural Health (UK CERH) and a network of community partners are joining forces to intensify efforts to increase vaccination rates in a 32-county region of Appalachia Kentucky and neighboring counties in West Virginia.

The book is edited by UK faculty members Dr. James W. Holsinger Jr. and Dr. F. Douglas Scutchfield.

A University of Kentucky team is linking with a nationally-known education innovator to move beyond what school was before the COVID-19 pandemic.

A new study led by UK virologist and College of Medicine Vice Dean for Research Becky Dutch reveals foundational characteristics of SARS-CoV-2's spike protein.